Samsung Biologics Co Ltd
KRX:207940
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Samsung Biologics Co Ltd
KRX:207940
|
KR |
|
G
|
Globant SA
F:2G2
|
LU |
|
Rockfire Resources PLC
LSE:ROCK
|
UK |
|
Build-A-Bear Workshop Inc
NYSE:BBW
|
US |
|
A
|
Archion Corp
TSE:543A
|
JP |
|
G
|
Gol Linhas Aereas Inteligentes SA
F:GOQN
|
BR |
|
Roper Technologies Inc
SIX:ROP
|
US |
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
Solar Industries India Ltd
NSE:SOLARINDS
|
IN |
|
E
|
Elica SpA
F:7L4
|
IT |
|
Ameresco Inc
NYSE:AMRC
|
US |
|
J
|
JD.Com Inc
F:013C
|
CN |
|
T
|
Teladoc Health Inc
SWB:4LL
|
US |
|
S
|
Spirit AeroSystems Holdings Inc
XMUN:S9Q
|
US |
|
Publicis Groupe SA
PAR:PUB
|
FR |
|
Mastercard Inc
NYSE:MA
|
US |
|
G
|
Global Net Lease Inc
F:2N8
|
US |
|
T
|
Thai Airways International PCL
SET:THAI
|
TH |
|
O
|
OM2 Network Co Ltd
TSE:7614
|
JP |
Wall St Price Targets
Price Targets Summary
Samsung Biologics Co Ltd
According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 2 152 184.01 KRW with a low forecast of 1 616 000 KRW and a high forecast of 2 421 619.24 KRW.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is Samsung Biologics Co Ltd's stock price target?
Price Target
2 152 184.01
KRW
According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 2 152 184.01 KRW with a low forecast of 1 616 000 KRW and a high forecast of 2 421 619.24 KRW.
What is the Revenue forecast for Samsung Biologics Co Ltd?
Projected CAGR
14%
Over the last 11 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 7 years is 14%.
What is the Gross Profit forecast for Samsung Biologics Co Ltd?
Projected CAGR
20%
The compound annual growth rate for Gross Profit over the next 3 years is 20%.
What is the Operating Income forecast for Samsung Biologics Co Ltd?
Projected CAGR
14%
The compound annual growth rate for Operating Income over the next 7 years is 14%.
What is the Pre-Tax Income forecast for Samsung Biologics Co Ltd?
Projected CAGR
16%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 16%.
What is the Net Income forecast for Samsung Biologics Co Ltd?
Projected CAGR
12%
The compound annual growth rate for Net Income over the next 3 years is 12%.
